According to a recent LinkedIn post from Parallel Fluidics, the company is emphasizing its LNP Screening Array as a tool designed to improve lab workflows and reproducibility. The post highlights predictable hardware performance, reduced hands-on time, and consistency in formulation work, with all arrays manufactured at its Boston facility.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that Parallel Fluidics plans to share additional information about the LNP Screening Array at the upcoming LNP Summit. For investors, this focus on high-throughput lipid nanoparticle screening and lab automation suggests a push to strengthen the company’s position within mRNA and LNP-related research workflows, potentially supporting future demand from biopharma and advanced therapeutics customers.